Lymphoseek 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3 
amended 
on 
T/0021 
Transfer of Marketing Authorisation 
06/08/2020 
24/09/2020 
SmPC, 
Labelling and 
PL 
II/0019 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
30/04/2020 
24/09/2020 
SmPC, Annex 
new quality, preclinical, clinical or pharmacovigilance 
data 
II, Labelling 
and PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
  
 
 
 
 
 
 
 
 
PSUSA/10313
Periodic Safety Update EU Single assessment - 
28/11/2019 
n/a 
PRAC Recommendation - maintenance 
/201905 
tilmanocept 
R/0016 
Renewal of the marketing authorisation. 
25/07/2019 
16/09/2019 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Lymphoseek in the approved indication remains favourable 
and therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
II/0017 
B.I.b.1.f - Change in the specification parameters 
25/07/2019 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Change outside the 
approved specifications limits range for the AS 
PSUSA/10313
Periodic Safety Update EU Single assessment - 
29/11/2018 
n/a 
PRAC Recommendation - maintenance 
/201805 
tilmanocept 
IAIN/0015/G 
This was an application for a group of variations. 
23/11/2018 
16/09/2019 
SmPC, Annex 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
II, Labelling 
and PL 
IA/0014/G 
This was an application for a group of variations. 
30/10/2018 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
Lymphoseek  
EMA/CHMP/574814/2020 
Page 2/6 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
PSUSA/10313
Periodic Safety Update EU Single assessment - 
14/06/2018 
n/a 
PRAC Recommendation - maintenance 
/201711 
tilmanocept 
PSUSA/10313
Periodic Safety Update EU Single assessment - 
30/11/2017 
n/a 
PRAC Recommendation - maintenance 
/201705 
tilmanocept 
IAIN/0011/G 
This was an application for a group of variations. 
16/11/2017 
08/08/2018 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0010 
B.II.e.5.a.2 - Change in pack size of the finished 
16/09/2017 
08/08/2018 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
Lymphoseek  
EMA/CHMP/574814/2020 
Page 3/6 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
PSUSA/10313
Periodic Safety Update EU Single assessment - 
09/06/2017 
n/a 
PRAC Recommendation - maintenance 
/201611 
tilmanocept 
T/0007 
Application for Transfer of Marketing Authorisation 
09/01/2017 
23/01/2017 
SmPC, 
from Navidea Biopharmaceuticals Limited to Norgine 
B.V. 
Labelling and 
PL 
Transfer of Marketing Authorisation 
PSUSA/10313
Periodic Safety Update EU Single assessment - 
01/12/2016 
n/a 
PRAC Recommendation - maintenance 
/201605 
tilmanocept 
IA/0006/G 
This was an application for a group of variations. 
25/11/2016 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.c.1.a - Change in immediate packaging of the AS 
- Qualitative and/or quantitative composition 
Lymphoseek  
EMA/CHMP/574814/2020 
Page 4/6 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
II/0004/G 
This was an application for a group of variations. 
15/09/2016 
23/01/2017 
SmPC, Annex 
II, Labelling 
and PL 
B.II.a.2.c - Change in the shape or dimensions of the 
pharmaceutical form - Addition of a new kit for a 
radiopharmaceutical preparation with another fill 
volume 
B.II.a.3.z - Changes in the composition (excipients) 
of the finished product - Other variation 
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.e.1.a.3 - Change in immediate packaging of the 
finished product - Qualitative and quantitative 
composition - Sterile medicinal products and 
biological/immunological medicinal products 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
Lymphoseek  
EMA/CHMP/574814/2020 
Page 5/6 
 
 
  
  
 
 
 
PSUSA/10313
Periodic Safety Update EU Single assessment - 
09/06/2016 
n/a 
PRAC Recommendation - maintenance 
/201511 
tilmanocept 
PSUSA/10313
Periodic Safety Update EU Single assessment - 
03/12/2015 
n/a 
PRAC Recommendation - maintenance 
/201505 
tilmanocept 
IB/0002 
B.II.d.2.d - Change in test procedure for the finished 
18/11/2015 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
Lymphoseek  
EMA/CHMP/574814/2020 
Page 6/6 
 
 
  
  
 
 
 
 
 
 
 
  
